---
title: "000963.SZ (000963.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000963.SZ/news.md"
symbol: "000963.SZ"
name: "000963.SZ"
parent: "https://longbridge.com/en/quote/000963.SZ.md"
datetime: "2026-03-04T10:49:58.455Z"
locales:
  - [en](https://longbridge.com/en/quote/000963.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000963.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000963.SZ/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/000963.SZ/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/000963.SZ/news.md)


# 000963.SZ (000963.SZ) — Related News

### [Huadong Medicine Obtains Greenlight for Cancer Drug Trial](https://longbridge.com/en/news/277569784.md)
*2026-03-03T06:11:53.000Z*
> Huadong Medicine Obtains Greenlight for Cancer Drug Trial

### [HUADONG MEDICINE: Clinical trial application for injectable DR30206 approved](https://longbridge.com/en/news/277450215.md)
*2026-03-02T10:58:45.000Z*
> HUADONG MEDICINE's subsidiary Zhejiang Daor Biotechnology Co., Ltd. has received approval from the National Medical Prod

### [Corporate Innovation Intelligence (February 13): Weibo releases the top ten trending "Internet figures" for 2025, with Lei Jun, Luo Yonghao, and Liu Qiangdong ranking in the top three](https://longbridge.com/en/news/275833879.md)
*2026-02-13T01:34:16.000Z*
> Weibo released the top ten trending "Internet figures" for 2025, with Lei Jun, Luo Yonghao, and Liu Qiangdong ranking in

### [HUADONG MEDICINE's self-developed ADC new drug injection HDM2020 for gastric cancer and gastroesophageal junction cancer has received orphan drug designation from the U.S. FDA](https://longbridge.com/en/news/275723487.md)
*2026-02-12T08:30:20.000Z*
> On February 12th, according to HUADONG MEDICINE, the wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co

### [HUADONG MEDICINE: KIO015 is currently in the technical review stage of the EU MDR-CE certification](https://longbridge.com/en/news/275257605.md)
*2026-02-09T02:05:24.000Z*
> On February 9th, HUADONG MEDICINE stated on the interactive platform that KIO015 is currently in the technical review st

### [HUADONG MEDICINE: The Phase II clinical trial for the second-generation highly selective JAK1 inhibitor VC005 for vitiligo has completed enrollment](https://longbridge.com/en/news/275245724.md)
*2026-02-09T00:52:14.000Z*
> Recently, the Phase II clinical study of the second-generation highly selective JAK1 inhibitor VC005 tablets for the ora

### [Huadong Medicine's Unit Gets Nod for Hypertriglyceridemia Drug Clinical Trial](https://longbridge.com/en/news/274912733.md)
*2026-02-05T04:20:12.000Z*
> Huadong Medicine's Unit Gets Nod for Hypertriglyceridemia Drug Clinical Trial

### [Corporate Innovation Intelligence (February 5): Didi collaborates with Hainan Airlines for membership launch; Mixue Ice City has registered snow](https://longbridge.com/en/news/274895593.md)
*2026-02-05T01:32:16.000Z*
> Didi collaborates with Hainan Airlines to launch membership services, and Mixue Ice City has registered a new brand. OFF

### [HUADONG MEDICINE: Clinical trial application for DR10624 injection approved](https://longbridge.com/en/news/274790886.md)
*2026-02-04T09:55:04.000Z*
> The clinical trial application for the DR10624 injection of Huadong Medicine's subsidiary Zhejiang Daor Biotechnology Co